Ladenburg Thalmann Maintains Buy on Eiger BioPharmaceuticals, Raises Price Target to $31

Ladenburg Thalmann maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Buy and raises the price target from $28 to $31.

Benzinga · 01/22/2020 13:18

Ladenburg Thalmann maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Buy and raises the price target from $28 to $31.